Table 6.

Effect modification by type 2 diabetes on the association between NGFR haplotypes and the risk of Alzheimer's disease stratified by ApoEε4 status

	NGFR variant non-carriers		NGFR variant carriers		Pinteraction
	Case/control	OR	Case/control	OR (95%CI)
ApoEε4 non-carriers
Hap1: GCGCG
Diabetes	23/23	1.00	8/21	0.28 (0.08-0.97)
Without diabetes	64/151	1.00	60/134	0.90 (0.53-1.51)	0.12
Hap2: GCTTG
Diabetes	15/29	1.00	17/15	2.79 (0.83-9.43)
Without diabetes	83/173	1.00	41/112	0.73 (0.42-1.26)	0.04
Hap3: GCTTA
Diabetes	22/34	1.00	9/10	1.17 (0.30-4.51)
Without diabetes	1.00	95/220	29/65	1.11 (0.57-2.14)	0.94
Hap4: GCTCA
Diabetes	22/36	1.00	9/8	1.91 (0.42-8.78)
Without diabetes	93/217	1.00	31/68	1.12 (0.59-2.11)	0.43
Hap5: GTTCG
Diabetes	26/27	1.00	5/17	0.50 (0.12-2.09)
Without diabetes	92/232	1.00	32/53	2.12 (1.13-3.99)	0.01
Hap6: GCTCG
Diabetes	26/39	1.00	5/5	2.50 (0.32-19.61)
Without diabetes	111/234	1.00	13/51	0.48 (0.21-1.10)	0.06
Hap7: TCTCG
Diabetes	25/41	1.00	6/3	7.15 (0.55-93.39)
Without diabetes	1.00	109/257	14/28	1.10 (0.48-2.54)	0.23
ApoEε4 carriers
Hap1: GCGCG
Diabetes	7/3	1.00	9/3	2.53 (0.19-33.57)
Without diabetes	52/25	1.00	39/24	0.64 (0.28-1.48)	0.71
Hap2: GCTTG
Diabetes	12/4	1.00	4/2	2.17 (0.13-35.20)
Without diabetes	48/28	1.00	43/21	1.04 (0.42-2.57)	0.82
Hap3: GCTTA
Diabetes	15/6	1.00	1/0	NA
Without diabetes	72/40	1.00	19/9	1.43 (0.47-4.31)	NA
Hap4: GCTCA
Diabetes	9/5	1.00	7/1	NA
Without diabetes	70/41	1.00	21/8	1.49 (0.48-4.60)	NA
Hap5: GTTCG
Diabetes	13/4	1.00	3/2	NA
Without diabetes	80/44	1.00	11/5	1.48 (0.35-6.26)	NA
Hap6: GCTCG
Diabetes	13/4	1.00	3/2	NA
Without diabetes	66/41	1.00	25/8	2.42 (0.74-7.95)	NA
Hap7: TCTCG
Diabetes	12/5	1.00	4/1	NA
Without diabetes	82/39	1.00	9/10	0.53 (0.16-1.72)	NA

All models were adjusted for age, sex, and education.

Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable.